Symptom management in isocitrate dehydrogenase mutant glioma
Recommended Citation
Walbert T, Avila EK, Boele FW, Hertler C, Lu-Emerson C, van der Meer PB, Peters KB, Rooney AG, Templer JW, and Koekkoek JAF. Symptom management in isocitrate dehydrogenase mutant glioma. Neurooncol Pract 2025; 12(Suppl 1):i38-i48.
Document Type
Article
Publication Date
2-1-2025
Publication Title
Neurooncol Pract
Abstract
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality. With new treatments that improve progression-free and possibly overall survival, preventing and addressing daily symptoms becomes even more clinically relevant. In this review we discuss the management of the most prevalent symptoms, including tumor-related epilepsy, cognitive dysfunction, mood disorders, and fatigue, in patients with mIDH glioma, and issues regarding patient's health-related quality of life and caregiver needs in the era of mIDH inhibitors. We provide recommendations for practicing healthcare professionals caring for patients who are eligible for treatment with mIDH inhibitors.
PubMed ID
39776527
Volume
12
Issue
Suppl 1
First Page
38
Last Page
38
